Table1:
Baseline characteristics of participants. Participants with prevalent CVD or diabetes at baseline excluded from the analyses.
| Characteristics | Non-HDL3 < 130 mg/dL (N=990) | Non-HDL 130–160 mg/dL (N=781) | Non-HDL ≥ 160 mg/dL (N=745) | Total Analytical Sample (N=2516) |
|---|---|---|---|---|
| Age at baseline (years) | 30.8 ± 3.9 | 31.2 ± 4.1 | 32.4 ± 4.1 | 31.4 ± 4.1 |
| Age at follow-up (years) | 63.5 ± 4.1 | 63.8 ± 4.3 | 65.0 ± 4.4 | 64.0 ± 4.3 |
| Men (%) | 29.1 | 49.0 | 69.5 | 47.3 |
| Average follow-up (years)* | 28.3 ± 7.0 | 27.4 ± 8.1 | 24.9 ± 9.3 | 27.0 ± 8.2 |
| Body Mass Index (kg/m2) | 23.2 ± 3.6 | 24.7 ± 4.3 | 26.4 ± 4.2 | 24.6 ± 4.2 |
| Dyslipidemia (%) | 0 | 8.6 | 81.6 | 26.8 |
| Hypertension (%) | 6.2 | 10.4 | 19.1 | 11.3 |
| Diabetes (%) | 0.0 | 0.0 | 0.0 | 0.0 |
| Treatment for Blood Pressure (%) | 0.5 | 1.3 | 1.9 | 1.2 |
| Treatment for Hypercholesterolemia (%) | 0 | 0 | 0.1 | 0.0 |
| Systolic Blood Pressure (mmHg) | 114.4 ± 12.3 | 117.8 ± 13.7 | 121.8 ± 13.7 | 117.7 ± 13.5 |
| Diastolic Blood Pressure (mmHg) | 73.6 ± 8.8 | 76.0 ± 9.8 | 79.6 ± 10.0 | 76.1 ± 9.8 |
| Total Cholesterol (mg/dL) | 162.1 ± 20.4 | 190.2 ± 18.2 | 227.2 ± 29.2 | 190.1 ± 35.2 |
| HDL Cholesterol (mg/dL) | 57.0 ± 14.7 | 50.3 ± 13.9 | 44.6 ± 13.2 | 51.2 ± 14.9 |
| Non-HDL Cholesterol (mg/dL) | 105.2 ± 17.5 | 139.9 ± 14.6 | 182.6 ± 29.0 | 138.9 ± 38.1 |
| LDL Cholesterol (mg/dL) | 92.4 ± 17.0 | 122.9 ± 15.2 | 158.0 ± 27.8 | 121.2 ± 33.8 |
| Triglycerides (mg/dL) | 63.8 ± 31.0 | 85.1 ± 47.6 | 121.0 ± 60.0 | 87.2 ± 51.9 |
means and standard deviations for continuous measurements; percent for categorical data.
1
Participants from Offspring exam 1 (follow-up to exam 8) and participants from Offspring exam 2 (follow-up to exam 9, only subjects who did not attend exam 1).
2
Participants with available non-HDL cholesterol and lipid treatment data.
*
Average follow-up for CVD survival time from second exam.
3
Non-HDL values for participants on treatment inflated by non-parametric adjustment.